Claritas Pharmaceuticals, Inc.
CLAZF · OTC
9/30/2021 | 6/30/2021 | 3/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | -0.00 | -0.00 |
| FCF Yield | -147.64% | 37.01% | -67.26% | -3,570.84% |
| EV / EBITDA | 1.06 | -2.41 | -0.32 | -0.33 |
| Quality | ||||
| ROIC | -13.42% | -13.73% | -7.02% | 51.36% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.11 | 0.16 | 0.14 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -306.62% | 141.98% | 33.06% | -281.27% |
| Safety | ||||
| Net Debt / EBITDA | 0.79 | -1.74 | -0.14 | -0.33 |
| Interest Coverage | -36.71 | -0.77 | -2.69 | 74.91 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |